bluebird bio, Inc. (NASDAQ:BLUE) Receives $44.14 Consensus PT from Brokerages

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received a consensus rating of “Hold” from the nine analysts that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $48.10.

Several analysts have recently commented on the stock. Baird R W downgraded shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Wells Fargo & Company reduced their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, February 24th. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and set a $80.00 price target on shares of bluebird bio in a research report on Friday, November 15th. Finally, Barclays increased their price target on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st.

bluebird bio Stock Performance

BLUE opened at $4.00 on Monday. The company’s fifty day moving average price is $7.11 and its two-hundred day moving average price is $8.75. The company has a market cap of $38.89 million, a price-to-earnings ratio of -0.11 and a beta of 0.76. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. bluebird bio has a 1-year low of $3.56 and a 1-year high of $33.20.

Institutional Investors Weigh In On bluebird bio

Several hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its holdings in shares of bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after acquiring an additional 186,903 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 355,562 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 77,293 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of bluebird bio in the 3rd quarter worth approximately $42,000. Finally, State Street Corp lifted its holdings in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after acquiring an additional 43,382 shares during the last quarter. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.